Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics (Nasdaq: VERA) named Matt Skelton Chief Commercial Officer, effective January 28, 2026. Skelton, previously Executive Vice President, Commercial, joined Vera over a year ago and will lead launch readiness for atacicept targeting IgA nephropathy.
Skelton’s background includes scaling Seagen’s commercial organization to four approved products and senior commercial roles at Amgen and Eli Lilly.
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted January 5, 2026 to 18 new employees under its 2024 Inducement Plan.
The Compensation Committee granted non-qualified stock options to purchase 228,750 shares and restricted stock units underlying 116,000 shares. Each option has an exercise price of $47.07, equal to the closing price on January 5, 2026.
Options vest over four years (25% at one year, then monthly over 36 months) subject to continued service; RSUs vest 25% on each anniversary of February 20, 2026 over four years. Awards are subject to the Inducement Plan and award agreements.
Vera Therapeutics (NASDAQ:VERA) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 2:15 PM PST.
The team will participate in one-on-one investor meetings and provide a live webcast at the conference link. A replay will be available for 90 days via the company's Investor Calendar.
Vera Therapeutics (NASDAQ: VERA) announced the U.S. FDA accepted its BLA for atacicept in adults with immunoglobulin A nephropathy (IgAN) and granted Priority Review with a PDUFA target action date of July 7, 2026.
The submission used the Accelerated Approval Program and follows Breakthrough Therapy designation. A prespecified interim analysis from the ORIGIN 3 trial showed atacicept reduced proteinuria by 46% from baseline and by 42% versus placebo (p<0.0001) at week 36. Results were presented at ASn Kidney Week and published in the New England Journal of Medicine on November 6, 2025. If approved, atacicept could be offered as a once-weekly subcutaneous autoinjector for at-home use.
Vera Therapeutics (NASDAQ: VERA) priced an underwritten public offering of 6,138,108 Class A shares at $42.50 per share, expected to raise approximately $261 million in gross proceeds before fees.
The company granted underwriters a 30-day option to buy up to an additional 920,716 shares at the public offering price. The offering is expected to close on December 11, 2025, subject to customary closing conditions. Joint book-runners include J.P. Morgan, Goldman Sachs, Evercore ISI and Cantor; LifeSci Capital is lead manager.
Vera Therapeutics (NASDAQ: VERA) announced on December 8, 2025 its intention to commence a public offering to issue and sell $200.0 million of Class A common stock, subject to market and other conditions.
The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares. The offering will be made from an existing Form S-3 shelf registration that became effective October 28, 2024, and a preliminary prospectus supplement will be filed with the SEC.
Vera Therapeutics (Nasdaq: VERA) announced that on December 2, 2025 its Compensation Committee granted inducement awards under the 2024 Inducement Plan to seven new employees. The awards include non-qualified stock options to purchase 42,000 shares and restricted stock units underlying 21,000 shares of Class A common stock.
Each option has an exercise price of $37.25 (Vera's closing price on December 2, 2025) and vests over four years (25% after one year, then monthly over 36 months). RSUs vest over four years with 25% vesting on each anniversary of November 20, 2025. Awards are subject to the Inducement Plan and applicable award agreements.
Vera Therapeutics (Nasdaq: VERA) announced the appointment of James R. Meyers to its Board of Directors on November 26, 2025. Meyers brings over 30 years of commercial leadership, including senior roles at Gilead and AstraZeneca, plus CEO experience at IntraBio and current board seats at Sangamo and CytomX.
Management said Meyers will support Vera as it prepares to launch atacicept next year as a potential first-in-class dual BAFF/APRIL inhibitor targeting IgA nephropathy and other autoimmune diseases.
Vera Therapeutics (Nasdaq: VERA) announced that management will present and hold one-on-one meetings at two investor conferences in early December 2025.
Events and logistics:
- Evercore Healthcare Conference — Fireside chat and 1x1s on Dec 2, 2025 at 8:45am ET in Coral Gables, FL; webcast: https://wsw.com/webcast/evercore52/vera/2362844
- Citi 2025 Global Healthcare Conference — Fireside chat and 1x1s on Dec 3, 2025 at 4:00pm ET in Miami, FL; webcast: https://kvgo.com/global-healthcare-conference-2025/vera-therapeutics-december-2025
A replay of the webcasts will be available for 90 days via the company’s Investor Calendar.
Vera Therapeutics (Nasdaq: VERA) announced that its management team will present at the TD Cowen Immunology & Inflammation Summit, held virtually on November 12-13, 2025. The company presentation is scheduled for Thursday, November 13, 2025 at 1:30pm ET.
Management will also hold one-on-one investor meetings. A live webcast is available at the provided link and a replay will be accessible for 90 days via the company’s Investor Calendar.
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
